DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Kim D-W, Saussele S, Williams LA. et al.
Outcomes of switching to Dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study.
Ann Hematol 2018;
97 (08) 1357-1367
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.